Table 8. Mean IOP (mmHg) by Treatment Group and Treatment Difference in Mean IOP in Response to Travatan and Izbaa.
| IOP
change from baseline (mmHg) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| IZBA |
TRAVATAN |
||||||||
| visit | N | 8 AM | 10 AM | 4 PM | N | 8 AM | 10 AM | 4 PM | |
| week 2 | mean | 442 | –8.0 | –7.3 | –7.1 | 416 | –8.1 | –7.5 | –7.1 |
| 95% CI | (−8.3, −7.7) | (−7.6, −7.0) | (−7.4, −6.8) | (−8.4, −7.8) | (−7.8, −7.2) | (−7.4, −6.8) | |||
| week 6 | mean | 440* | –8.1 | –7.4 | –7.2 | 413 | –8.3 | –7.5 | –7.2 |
| 95% CI | (−8.4, −7.9) | (−7.6, −7.1) | (−7.5, −6.9) | (−8.7, −8.0) | (−7.9, −7.2) | (−7.5, −6.9) | |||
| month 3 | mean | 432* | –8.2 | –7.5 | –7.1 | 408 | –8 4 | –7.6 | –7.3 |
| 95% CI | (−8.6, −7.9) | (−7.9, −7.2) | (−7.4, −6.8) | (−8.7, –8.1) | (−7.9, −7 2) | (−7.7, −7.0) | |||
| visit/time point | IZBA (Travoprost 0.003%) | TRAVATAN (Travaprost 0.004%) | Difference |
|---|---|---|---|
| mean (SE) | mean (SE) | mean (95% CI) * | |
| baseline | (N = 442) | (N = 418) | |
| 8 AM | 26.9 (0.12) | 27.1 (0.14) | –0.2 (−0.5 0.2) |
| 10 AM | 25.4 (0.13) | 25.6 (0.15) | –0.2 (−0.6 0.2) |
| 4 PM | 24.6 (0.14) | 24.8 (0.16) | –0.2 (−0.6 0.2) |
| week 2 | (N = 442) | (N = 416) | |
| 8 AM | 19.4 (0.16) | 19.5 (0.17) | –0.1 (−0.5 0.3) |
| 10 AM | 18.6 (0.16) | 18.6 (0.16) | –0.0 (−0.4 0.4) |
| 4 PM | 18.0 (0.16) | 18.3 (0.16) | –0.3 (−0.7 0.1) |
| week 6 | (N = 440**) | (N = 413) | |
| 8 AM | 19.3 (0.16) | 19.3 (0.17) | –0.0 (−0.4 0.4) |
| 10 AM | 18.5 (0.16) | 18.6 (0.17) | –0.1 (−0.5 0.3) |
| 4 PM | 18.0 (0.16) | 18.1 (0.17) | –0.2 (−0.6 0.2) |
| month 3 | (N = 432**) | (N = 408) | |
| 8 AM | 19.2 (0.17) | 19.3 (0.18) | –0.1 (−0.5 0.3) |
| 10 AM | 18.3 (0.17) | 18.6 (0.18) | –0.3 (−0.7 0.1) |
| 4 PM | 18.0 (0.16) | 18.0 (0.17) | 0.0 (−0.4 0.4) |
a
Data are from the package insert of Izba that compares the IOP-lowering efficacy with Travatan. The asterisks (∗) indicate statistical significance.